PE20140198A1 - Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima - Google Patents

Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima

Info

Publication number: PE20140198A1
Authority: PE; Peru
Prior art keywords: amidobenzyl; dipeptide; linked; coupling; binder
Prior art date: 2010-12-29

Application number

PE2013001496A

Other languages

English (en)

Spanish (es)

Inventor

David B Rozema

David L Lewis

Darren H Wakefield

Eric A Kitas

Philipp Hadwiger

Jon A Wolff

Ingo Roehl

Peter Mohr

Torsten Hoffmann

Kerstin Jahn-Hofmann

Hans Martin Mueller

Guenther Ott

Andrei V Blokhin

Jeffrey C Carlson

Jonathan D Benson

Original Assignee

Arrowhead Res Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-29

Filing date

2011-12-28

Publication date

2014-02-21

2011-12-23 Priority claimed from US13/336,028 external-priority patent/US8426554B2/en

2011-12-28 Application filed by Arrowhead Res Corp filed Critical Arrowhead Res Corp

2014-02-21 Publication of PE20140198A1 publication Critical patent/PE20140198A1/es

Links

102000040430 polynucleotide Human genes 0.000 title abstract 3
108091033319 polynucleotide Proteins 0.000 title abstract 3
239000002157 polynucleotide Substances 0.000 title abstract 3
102000004190 Enzymes Human genes 0.000 title 1
108090000790 Enzymes Proteins 0.000 title 1
230000008878 coupling Effects 0.000 abstract 3
238000010168 coupling process Methods 0.000 abstract 3
238000005859 coupling reaction Methods 0.000 abstract 3
102000005427 Asialoglycoprotein Receptor Human genes 0.000 abstract 2
239000002202 Polyethylene glycol Substances 0.000 abstract 2
230000003213 activating effect Effects 0.000 abstract 2
108010006523 asialoglycoprotein receptor Proteins 0.000 abstract 2
239000011230 binding agent Substances 0.000 abstract 2
OVHQWOXKMOVDJP-UHFFFAOYSA-N melitin Chemical compound OC1C(O)C(O)C(C)OC1OC1C(O)C(OC=2C=C3C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)=C(C=4C=CC(O)=CC=4)O3)=O)=C(O)C=2)OC(C)C1O OVHQWOXKMOVDJP-UHFFFAOYSA-N 0.000 abstract 2
229920000768 polyamine Polymers 0.000 abstract 2
229920001223 polyethylene glycol Polymers 0.000 abstract 2
229920000642 polymer Polymers 0.000 abstract 2
239000003381 stabilizer Substances 0.000 abstract 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
206010073069 Hepatic cancer Diseases 0.000 abstract 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 abstract 1
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 abstract 1
238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
229930182830 galactose Natural products 0.000 abstract 1
230000009368 gene silencing by RNA Effects 0.000 abstract 1
210000003494 hepatocyte Anatomy 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
239000008101 lactose Substances 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
201000007270 liver cancer Diseases 0.000 abstract 1
208000014018 liver neoplasm Diseases 0.000 abstract 1
239000012528 membrane Substances 0.000 abstract 1
150000003141 primary amines Chemical class 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/96—Esters of carbonic or haloformic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/91—Polymers modified by chemical after-treatment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/95—Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Polymers & Plastics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PE2013001496A 2010-12-29 2011-12-28 Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima PE20140198A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201061427936P	2010-12-29	2010-12-29
US13/336,028 US8426554B2 (en)	2010-12-29	2011-12-23	In vivo polynucleotide delivery conjugates having enzyme sensitive linkages

Publications (1)

Publication Number	Publication Date
PE20140198A1 true PE20140198A1 (es)	2014-02-21

Family

ID=46383848

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2013001496A PE20140198A1 (es)	2010-12-29	2011-12-28	Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima

Country Status (15)

Country	Link
EP (1)	EP2658579A4 (fr)
JP (1)	JP5941926B2 (fr)
KR (1)	KR20130136494A (fr)
CN (1)	CN103491982B (fr)
AU (1)	AU2011352204B2 (fr)
BR (1)	BR112013014115A2 (fr)
CA (1)	CA2816041C (fr)
CL (2)	CL2013001876A1 (fr)
MX (2)	MX341118B (fr)
NZ (1)	NZ611656A (fr)
PE (1)	PE20140198A1 (fr)
RU (1)	RU2619453C2 (fr)
SG (1)	SG189942A1 (fr)
WO (1)	WO2012092373A2 (fr)
ZA (1)	ZA201302896B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104837996A (zh)	2012-11-15	2015-08-12	罗氏创新中心哥本哈根有限公司	抗apob反义缀合物化合物
WO2015021092A1 (fr) *	2013-08-07	2015-02-12	Arrowhead Research Corporation	Polyconjugués pour l'administration de déclencheurs d'arni à des cellules tumorales in vivo
JOP20160211B1 (ar)	2015-10-01	2021-08-17	Arrowhead Pharmaceuticals Inc	تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
JP2019513371A (ja)	2016-04-01	2019-05-30	アビディティーバイオサイエンシーズエルエルシー	核酸ポリペプチド組成物とその使用
JP2020520981A (ja) *	2017-05-24	2020-07-16	ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドＲａｍｏｔＡｔＴｅｌＡｖｉｖＵｎｉｖｅｒｓｉｔｙＬｔｄ．	プロテアーゼのイメージング／検出のための化学発光プローブ
AU2018378812B2 (en)	2017-12-06	2025-05-22	Avidity Biosciences, Inc.	Compositions and methods of treating muscle atrophy and myotonic dystrophy
WO2020139788A2 (fr) *	2018-12-28	2020-07-02	Sirnaomics, Inc.	Administration ciblée de molécules thérapeutiques
CN114450326B (zh) *	2019-06-24	2025-02-11	普罗美加公司	用于将生物分子递送到细胞中的改性聚胺聚合物
WO2021188390A1 (fr)	2020-03-19	2021-09-23	Avidity Biosciences, Inc.	Compositions et méthodes de traitement d'une dystrophie musculaire facio-scapulo-humérale
CA3198230A1 (fr) *	2021-01-28	2022-08-04	Jian Chen	Conjugue et son utilisation
WO2022270607A1 (fr) *	2021-06-24	2022-12-29	株式会社東北テクノアーチ	Sondes fluorescentes
KR102712976B1 (ko) *	2021-07-27	2024-10-07	국립안동대학교 산학협력단	등검은말벌 추출물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
CN113621003B (zh) *	2021-09-10	2023-02-03	国科温州研究院(温州生物材料与工程研究所)	一种制备有机分子共价修饰的功能化核酸材料的方法及其应用
CN118265544A (zh)	2021-09-16	2024-06-28	艾维迪提生物科学公司	治疗面肩肱型肌营养不良的组合物和方法
EP4710949A1 (fr) *	2023-05-12	2026-03-18	Goryo Chemical, Inc.	Préparation lyophilisée, solution lyophilisée, leurs procédés de production et agent liquide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6214345B1 (en) *	1993-05-14	2001-04-10	Bristol-Myers Squibb Co.	Lysosomal enzyme-cleavable antitumor drug conjugates
US6180095B1 (en) *	1997-12-17	2001-01-30	Enzon, Inc.	Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
CA2395636A1 (fr) *	1999-12-30	2001-07-12	Novartis Ag	Nouveaux vecteurs synthetiques colloides destines a la therapie genique
AU783679B2 (en) *	2000-02-24	2005-11-24	Genentech Inc.	Caspase activated prodrugs therapy
EP1243276A1 (fr) *	2001-03-23	2002-09-25	Franciscus Marinus Hendrikus De Groot	Prodrogues activables à séparateurs allongés et multiples
US7091186B2 (en) *	2001-09-24	2006-08-15	Seattle Genetics, Inc.	p-Amidobenzylethers in drug delivery agents
US7541330B2 (en) *	2004-06-15	2009-06-02	Kosan Biosciences Incorporated	Conjugates with reduced adverse systemic effects
WO2007059404A2 (fr) *	2005-11-10	2007-05-24	Medarex, Inc.	Composes et conjugues cytotoxiques
CN101500548A (zh) *	2006-08-18	2009-08-05	弗·哈夫曼-拉罗切有限公司	用于体内递送多核苷酸的多缀合物
RU2430740C2 (ru) *	2006-08-18	2011-10-10	Ф.Хоффманн-Ля Рош Аг	Поликонъюгаты для введения in vivo полинуклеотидов
AU2007343610C1 (en) *	2007-01-17	2013-11-07	Immunomedics, Inc.	Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
TW201004647A (en) *	2008-05-20	2010-02-01	Sigma Tau Ind Farmaceuti	Novel dual targeting antitumoural conjugates
US8501930B2 (en) *	2010-12-17	2013-08-06	Arrowhead Madison Inc.	Peptide-based in vivo siRNA delivery system

2011
- 2011-12-28 CA CA2816041A patent/CA2816041C/fr active Active
- 2011-12-28 JP JP2013547648A patent/JP5941926B2/ja not_active Expired - Fee Related
- 2011-12-28 RU RU2013117286A patent/RU2619453C2/ru active
- 2011-12-28 SG SG2013029830A patent/SG189942A1/en unknown
- 2011-12-28 PE PE2013001496A patent/PE20140198A1/es not_active Application Discontinuation
- 2011-12-28 KR KR1020137017195A patent/KR20130136494A/ko not_active Ceased
- 2011-12-28 BR BR112013014115A patent/BR112013014115A2/pt not_active IP Right Cessation
- 2011-12-28 EP EP11853858.6A patent/EP2658579A4/fr not_active Withdrawn
- 2011-12-28 MX MX2013007316A patent/MX341118B/es active IP Right Grant
- 2011-12-28 WO PCT/US2011/067588 patent/WO2012092373A2/fr not_active Ceased
- 2011-12-28 MX MX2016006733A patent/MX347298B/es unknown
- 2011-12-28 AU AU2011352204A patent/AU2011352204B2/en not_active Ceased
- 2011-12-28 NZ NZ611656A patent/NZ611656A/en not_active IP Right Cessation
- 2011-12-28 CN CN201180061179.6A patent/CN103491982B/zh active Active
2013
- 2013-04-22 ZA ZA2013/02896A patent/ZA201302896B/en unknown
- 2013-06-25 CL CL2013001876A patent/CL2013001876A1/es unknown
2015
- 2015-12-10 CL CL2015003580A patent/CL2015003580A1/es unknown

Also Published As

Publication number	Publication date
CL2015003580A1 (es)	2016-07-15
JP2014505685A (ja)	2014-03-06
CA2816041C (fr)	2019-01-08
CL2013001876A1 (es)	2014-04-11
MX2013007316A (es)	2013-07-29
EP2658579A2 (fr)	2013-11-06
AU2011352204B2 (en)	2015-05-21
EP2658579A4 (fr)	2015-07-22
WO2012092373A3 (fr)	2013-10-24
SG189942A1 (en)	2013-06-28
CN103491982B (zh)	2017-09-12
BR112013014115A2 (pt)	2019-09-24
AU2011352204A1 (en)	2013-05-02
NZ611656A (en)	2014-10-31
JP5941926B2 (ja)	2016-06-29
MX347298B (es)	2017-04-21
CA2816041A1 (fr)	2012-07-05
CN103491982A (zh)	2014-01-01
KR20130136494A (ko)	2013-12-12
RU2619453C2 (ru)	2017-05-16
WO2012092373A2 (fr)	2012-07-05
ZA201302896B (en)	2014-07-25
RU2013117286A (ru)	2015-03-10
MX341118B (es)	2016-08-09

Legal Events

Date	Code	Title	Description
2018-05-30	FC	Refusal

Publication	Publication Date	Title
PE20140198A1 (es)	2014-02-21	Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima
WO2009123768A3 (fr)	2009-12-03	Compositions de nanosupport et de nanogel
Lächelt et al.	2014	Fine-tuning of proton sponges by precise diaminoethanes and histidines in pDNA polyplexes
NZ601737A (en)	2013-06-28	Compositions for targeted delivery of sirna
MX2022008629A (es)	2022-08-08	Nanoparticulas lipidicas para la administracion de farmacos in vivo, y usos de las mismas.
WO2009095479A3 (fr)	2009-10-01	Promédicament comprenant un conjugué médicament-lieur
UY31543A1 (es)	2009-05-29	Sistema de administracion de rnai de interferencia y usos del mismo
NZ776256A (en)	2025-06-27	Therapeutic methods
IN2014DN00101A (fr)	2015-05-15
MX2021012934A (es)	2022-04-06	Lipidos de amina ionizables y nanoparticulas lipidicas.
PE20140180A1 (es)	2014-02-21	SISTEMA DE ADMINISTRACION DE ARNip IN VIVO BASADO EN PEPTIDOS
MX2011009808A (es)	2011-09-30	Agentes de elaboracion de imagen optica.
WO2007069068A3 (fr)	2007-09-13	Conjugués peptidiques de pénétration cellulaire pour la délivrance d'acides nucléiques dans une cellule
MY158228A (en)	2016-09-15	Factor ix conjugates with extended half-lives
TN2012000417A1 (en)	2014-01-30	Compounds as bradykinin b1 antagonists
AR082995A1 (es)	2013-01-23	Profarmacos que comprenden un conjugado de conector de exendina
CO6361910A2 (es)	2012-01-20	Pirrolidina-2-carboxamidas sustituidas
BR112014002191A2 (pt)	2017-03-07	amidas de ácido n-(tetrazol-5-il)- e n-(triazol-5-il)arilcarboxílico e seu uso como herbicidas
MY156951A (en)	2016-04-15	Micromirs
EP4321177A3 (fr)	2024-05-08	Conjugués glucidiques utilisés comme agents d'administration pour des oligonucléotides
HK1198629A1 (en)	2015-05-22	High-loading water-soluble carrier-linked prodrugs
MX2012013375A (es)	2013-04-11	Peptido c pegilado.
BR112017012482A2 (pt)	2018-02-27	copolímero estático, composição, uso de um copolímero, e, métodos para liberar um ácido nucleico a uma célula ou tecido alvo e para a produção do copolímero.
WO2011070440A3 (fr)	2011-09-01	Rhabdovirus oncolitique
HK1209045A1 (en)	2016-03-24	Pegylated oxm variants